These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19791828)

  • 21. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin.
    Henness S; Keam SJ
    Drugs; 2006; 66(15):1989-2001; discussion 2002-4. PubMed ID: 17100408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
    DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
    Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saxagliptin: A Review in Type 2 Diabetes.
    Dhillon S
    Drugs; 2015 Oct; 75(15):1783-96. PubMed ID: 26403305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
    Gallwitz B
    Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Dhillon S
    Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin + saxagliptin for type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):139-46. PubMed ID: 22149373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
    McFarland MS; Brock M; Ryals C
    South Med J; 2011 Jun; 104(6):426-39. PubMed ID: 21886033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.